Why the Cronos Group Stock Price Fell 18.3% in February

Cronos Group stock price tumbles on delay of earnings results due to accounting review, placing revenue growth into question.

| More on:
Question marks in a pile

Image source: Getty Images

The Cronos Group Inc. (TSX:CRON)(NASDAQ:CRON) stock price fell 18.3% in February. The market continues to fall and company-specific uncertainty remains high. This is making any prediction for the Cronos Group stock price very uncertain and precarious.

Fears of the potential severity of the coronavirus have ruled the market since February. This certainly continues today. As I write this article, I am struck by the downside that we are seeing. Cronos Group must deal not only with this, but also with sector and company-specific problems.  Let’s take a closer look.

Cronos Group stock price falls on results release delay

Cronos Group took the unusual move of delaying the release of its fourth-quarter and year-end 2019 results. Obviously, this took the stock down hard in February. We can only imagine what bad news awaits us from Cronos Group.

The earnings release was initially scheduled for February 27.  But a few days before this date, the company notified investors that there was a delay in the completion of financial statements. A few days later, the company filed a form 12b-25 with the U.S. Securities and Exchange Commission (SEC). This effectively provides the company with a 15-day extension of the filing due date. At this point, we are just waiting for this dreaded release.

Accounting review uncertainty to continue to take Cronos stock price down

The issue here is quite alarming. In the company’s SEC filing to delay the release, we got somewhat of an explanation. The accounting review is a review “of several bulk resin purchases and sales of products through the wholesale channel”. “The appropriateness of the recognition of revenue from those transactions” is being questioned. This effectively places past as well as future revenue growth into question.

The accounting issue also compounds the already existing problems in the cannabis sector. Problems such as a troubled legalization process in Canada and an oversupply of cannabis have taken a toll. A general bubble-like mentality in cannabis stock prices have already wreaked havoc on the sector.

On the positive side, Cronos Group remains well supported by its partnership with tobacco giant Altria Group Inc. This partnership has given Cronos Group greater financial capacity as well as leading technology and research and development capabilities. This partnership brings benefits to Cronos in distribution, capacity, brand development, and intellectual property.

Financially, Cronos Group reported revenue of $12.7 million in its latest released quarter (Q3 2019). This represents a 24% increase versus the prior quarter and a 238% increase versus the prior year. Cronos Group had $2 billion in cash as of the third quarter, and a cash burn of $100 million. Cronos stock price valuation remains problematic, at 77 times sales.

Going forward, this accounting review has placed a serious amount of uncertainty on the future of Cronos Group stock price. This, at a time when market uncertainty continues to escalate to near unprecedented levels.

Foolish bottom line

Cronos Group stock price suffered in February due to a combination of both macro factors, and sector and company-specific factors. The stock continues to be very richly valued. With revenue growth being put into question, the risk to the stock price remains high.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Karen Thomas has no position in any of the stocks mentioned.

More on Cannabis Stocks

Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.
Cannabis Stocks

Canopy Growth: Is There Budding Potential in the Cannabis Market?

Canopy Growth stock hit 52-week lows recently on news of needing to re-file on its BIoSteel business, so what now?

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

What’s Happening With Cannabis Stocks in May 2023?

Cannabis stocks were up this week, as the market began to turn, but how long will it last, and is…

Read more »

Cannabis smoke
Cannabis Stocks

Are Cannabis Stocks a Good Buy in May 2023?

If you're going to buy cannabis stocks, these are pretty much the only two I would consider. Even so, you…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Aurora Cannabis: Time to Light Up Your Portfolio?

Here's my take on whether Aurora Cannabis (TSX:ACB) is worth adding to a growth portfolio right now, given its growth…

Read more »

Target. Stand out from the crowd
Tech Stocks

These Undervalued TSX Stocks Are a Bargain in May 2023

If you're willing to bet on a rebound, these are the three TSX stocks I would consider first as they…

Read more »

A cannabis plant grows.
Cannabis Stocks

Tilray Stock Is Scraping 52-Week Lows: Will it Bottom Out Soon?

Tilray (TSX:TLRY) stock remains down 53% in the last year, but when will this company hit the bottom and start…

Read more »

Medicinal research is conducted on cannabis.
Metals and Mining Stocks

2 Canadian Stocks That Are Simply Too Cheap to Avoid

These two Canadian stocks have sunk lower and lower, which is why now could be the right time for long-term…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

1 Marijuana Stock I’d Buy Over Aurora Cannabis

Explore a promising marijuana stock that outshines Aurora Cannabis. Unveil the investment opportunity to boost your cannabis portfolio.

Read more »